Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
- Registration Number
- NCT04530344
- Lead Sponsor
- Incyte Corporation
- Brief Summary
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who have completed either Study NCT04052425 or NCT04057573 (parent studies) in which the participants will have been using ruxolitinib cream BID for the previous 28 to 52 weeks depending on their initial randomization in the parent study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 458
- Currently enrolled and receiving treatment in INCB 18424-306 (NCT04052425) or INCB 18424-307 (NCT04057573) studies evaluating ruxolitinib cream in participants with vitiligo.
- Currently tolerating ruxolitinib cream in the parent study and no safety concerns per investigators judgment.
- Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
- Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this protocol.
- Male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child.
- Ability to comprehend and willingness to sign an ICF or written informed consent of the parent(s) or legal guardian and written assent from the participant when possible.
- Has been permanently discontinued from study treatment in the parent study for any reason.
- Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.
- Pregnant or breastfeeding woman.
- Participants who live with anyone participating in any current Incyte-sponsored ruxolitinib cream study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort A : ruxolitinib cream ruxolitinib Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream. Cohort A : Vehicle Vehicle Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream. Cohort B : roxolitinib cream ruxolitinib Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream.
- Primary Outcome Measures
Name Time Method Time to Relapse (Defined as <F-VASI75) from Week 52 (first visit of this Treatment Extension study) to Week 104 (end of treatment in this Treatment Extension study) Relapse was defined as a loss of 75% improvement from Baseline in the Face Vitiligo Area Scoring Index score (F-VASI75) response, assessed as percentage improvement in the F-VASI score at Baseline (Day 1 of the parent study) to \<75%.
- Secondary Outcome Measures
Name Time Method Time to Loss of Adequate Response from Week 52 (first visit of this Treatment Extension study) to Week 104 (end of treatment in this Treatment Extension study) Loss of adequate response was defined as a loss of 90% improvement from Baseline in the F-VASI score (F-VASI90) response, assessed as percentage improvement in the F-VASI score at Baseline (Day 1 of the parent study) to \<90%.
Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score During the Extension Treatment Period up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Percentage of Participants Achieving a ≥75% Improvement From Baseline in the F-VASI (F-VASI75) Score During the Extension Treatment Period up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Percentage of Participants Achieving a ≥90% Improvement From Baseline in the F-VASI (F-VASI90) Score During the Extension Treatment Period up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Mean F-VASI Scores During the Extension Treatment Period up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Change From Baseline in F-VASI Scores During the Extension Treatment Period Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Percent Change From Baseline in F-VASI Scores During the Extension Treatment Period Baseline (BL); up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Percentage of Participants Achieving a ≥75% Improvement From Baseline in the T-VASI (T-VASI75) Score During the Extension Treatment Period up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) A T-VASI75 responder achieved at least 75% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Mean T-VASI Scores During the Extension Treatment Period up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score During the Extension Treatment Period up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Percentage of Participants Achieving a ≥90% Improvement From Baseline in the T-VASI (T-VASI90) Score During the Extension Treatment Period up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) A T-VASI90 responder achieved at least 90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Change From Baseline in T-VASI Scores During the Extension Treatment Period Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from Baseline=post-Baseline value minus the Baseline value.
Percent Change From Baseline in T-VASI Scores During the Extension Treatment Period Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Mean Facial Body Surface Area (F-BSA) During the Extension Treatment Period up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Data are presented as the percentage of BSA involvement in the face as compared to total BSA.
Change From Baseline in F-BSA During the Extension Treatment Period Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented as the percentage of BSA involvement in the face as compared to total BSA.
Percent Change From Baseline in F-BSA During the Extension Treatment Period Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
Mean Total Body Surface Area (T-BSA) During the Extension Treatment Period up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Data are presented as the percentage of BSA involvement in the total body.
Change From Baseline in T-BSA During the Extension Treatment Period Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented as the percentage of BSA involvement in the total body.
Percent Change From Baseline in T-BSA During the Extension Treatment Period Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) Score of 4 or 5 During the Extension Treatment Period Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.
Change From Week 52 in Dermatology Life Quality Index (DLQI) Total Score During the Extension Treatment Period Week 52; up to up to Week 104 of Extension Study (Week 52 was the first visit of this Treatment Extension study.) The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Participants age ≥16 years answered the questionnaire with: (1) very much; (2) a lot; (3) a little; or (4) not at all. The questionnaire was analyzed under 6 headings: Symptoms and feelings (Questions 1 and 2); Daily activities (Questions 3 and 4); Leisure (Questions 5 and 6); Work and school (Question 7); Personal relations (Questions 8 and 9); and Treatment (Question 10). The scoring of each question is as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "prevented work or studying"=3. The total score ranges from 0 to 30; higher scores indicate higher quality of life. Change from Week 52 was calculated as the post-Week 52 value minus the Week 52 value.
Change From Week 52 in Children's Dermatology Life Quality Index (CDLQI) Total Score During the Extension Treatment Period Week 52; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.) The CDLQI is the youth/children's version of the DLQI. The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Participants age \<16 years answered the questionnaire with: (1) very much; (2) a lot; (3) a little; or (4) not at all. The questionnaire was analyzed under 6 headings: Symptoms and feelings (Questions 1 and 2); Leisure (Questions 4, 5, and 6); School or holidays (Question 7); Personal relationships (Questions 3 and 8); Sleep (Question 9); and Treatment (Question 10). The scoring of each question is as follows: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. The total score ranges from 0 to 30; higher scores indicate higher quality of life. Change from Week 52 was calculated as the post-Week 52 value minus the Week 52 value.
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) up to approximately Week 108 (Week 52 was the first visit of this Treatment Extension study.) A TEAE was defined as any adverse event (AE) reported for the first time or the worsening of a pre-existing event after the first application of study drug in this study. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.
Trough Plasma Concentrations of Ruxolitinib at Week 80 and Week 104 Weeks 80 (predose); Week 104 (any time post-dose) (Week 52 was the first visit of this Treatment Extension study.) The steady-state plasma concentration was assessed. Pharmacokinetic blood samples could have been collected at any time prior to study drug application at the site at the Week 80 visit and at any time at the Week 104 (End of Trial) visit. Results from the two parent studies indicated that steady state was reached at or before Week 4, and that, hence, the use of vehicle or ruxolitinib 1.5% in the first 52 weeks of treatment had no impact on the ruxolitinib plasma concentration at the Week 80 and Week 104 (End of Treatment) visits. Thus, the two Cohort B cohorts were combined into a single arm for data analysis in this study.
Trial Locations
- Locations (84)
First Oc Dermatology
🇺🇸Fountain Valley, California, United States
Dermatology Research Associates
🇺🇸Los Angeles, California, United States
Advanced Pharma
🇺🇸Miami, Florida, United States
The Dermatology and Laser Center of San Antonio
🇺🇸San Antonio, Texas, United States
Minnesota Clinical Study Center
🇺🇸Minneapolis, Minnesota, United States
Diagnostic Consultative Center Ii Sofia Eood
🇧🇬Sofia, Bulgaria
Synexus - Sp Z Oo Oddzial W Katowice
🇵🇱Katowice, Poland
Dermmedica Sp. Z O.O.
🇵🇱Wroclaw, Poland
Lubeskie Centrum Diagnostyczne
🇵🇱Swidnik, Poland
University Multiprofile Hospital For Active Treatment Aleksandrovska
🇧🇬Sofia, Bulgaria
Synexus Affiliate - Krakowskie Centrum Medyczne
🇵🇱Krakow, Poland
Medical Center Unimed Eood
🇧🇬Sevlievo, Bulgaria
Synexus Polska Sp. Z O.O. Oddzial Warszawie
🇵🇱Warsaw, Poland
High-Med Przychodnia Specjalistycza
🇵🇱Warsaw, Poland
Synexus - Polska Sp Z Oo Oddzial W Gdansk
🇵🇱Gdansk, Poland
Synexus Polska Sp. Z O.O. Oddzial W Gdyni
🇵🇱Gdynia, Poland
Synexus Polska Sp. Z O.O. Oddzial W Poznaniu
🇵🇱Poznan, Poland
Poradnia Dermatologiczno-Wenerologiczna Mediderm S.C. Nzoz
🇵🇱Torun, Poland
Icahn School of Medicine At Mount Sinai
🇺🇸New York, New York, United States
Dermedic Dr. Zdybski
🇵🇱OSTROWIEC Swietokrzyski, Poland
Synexus Polska Sp. Z O.O. Oddzial We Wroclawiu
🇵🇱Wroclaw, Poland
Synexus Polska Sp Z Oo Oddzial W Lodzi
🇵🇱Lodz, Poland
Synexus Polska Sp Z Oo Oddzial W Czestochowie
🇵🇱Lublin, Poland
University of California San Francisco
🇺🇸San Francisco, California, United States
Henry Ford Medical Center
🇺🇸Detroit, Michigan, United States
Cahaba Dermatology
🇺🇸Hoover, Alabama, United States
Desert Sky Dermatology
🇺🇸Gilbert, Arizona, United States
Palmetto Clinical Trial Services
🇺🇸Anderson, South Carolina, United States
Tufts Medical Center
🇺🇸Boston, Massachusetts, United States
Dermatology Specialists of Spokane
🇺🇸Spokane, Washington, United States
Central Sooner Research
🇺🇸Norman, Oklahoma, United States
Delricht Clinical Research - Clinedge - Ppds Baton Rouge
🇺🇸Baton Rouge, Louisiana, United States
Suny Downstate Medical Center
🇺🇸Brooklyn, New York, United States
Metro Boston Clinical Partners
🇺🇸Brighton, Massachusetts, United States
Harmony Medical Research Institute
🇺🇸Hialeah, Florida, United States
Leavitt Medical Associates of Florida
🇺🇸Ormond Beach, Florida, United States
Randall Dermatology
🇺🇸West Lafayette, Indiana, United States
Great Lakes Research Group Inc
🇺🇸Bay City, Michigan, United States
Metabolic Research Institute Inc
🇺🇸West Palm Beach, Florida, United States
Derm Research Center of New York Inc
🇺🇸Stony Brook, New York, United States
K. Papp Clinical Research
🇨🇦Waterloo, Ontario, Canada
Simcoderm Medical and Surgical Dermatology Center
🇨🇦Barrie, Ontario, Canada
Kingsway Clinical Research
🇨🇦Etobicoke, Ontario, Canada
Jdr Dermatology Research
🇺🇸Las Vegas, Nevada, United States
International Clinical Research Tennessee Llc
🇺🇸Murfreesboro, Tennessee, United States
The Dermatology Specialists Greenwich
🇺🇸New York, New York, United States
Diagnostic Consultative Center Xxviii - Sofia - Eood
🇧🇬Sofia, Bulgaria
Lynderm Research Inc
🇨🇦Markham, Ontario, Canada
Xlr8 Medical Research
🇨🇦Windsor, Ontario, Canada
Ico Hospital Germans Trias I Pujol
🇪🇸Badalona, Spain
Hautarztpraxis Mahlow
🇩🇪Mahlow, Germany
Universitaetsklinikum Carl Gustav Carus
🇩🇪Dresden, Germany
Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
🇩🇪Mainz, Germany
Amsterdam University Medical Centre
🇳🇱Amsterdam, Netherlands
Universitatsklinik Munster Dermatologie
🇩🇪Muenster, Germany
Dermomedic
🇪🇸Madrid, Spain
Le Bateau Blanc
🇫🇷Martigues, France
Centre Hospitalier Universitaire de Bordeaux - Hospital Haut-Leveque
🇫🇷Pessac, France
Chu de Toulouse Hopital Larrey Centre de Reference Des Maladies Rares de La Peau Service de Dermatol
🇫🇷Toulouse, France
San Marcus Research Clinic Inc.
🇺🇸Miami Lakes, Florida, United States
Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume
🇫🇷Rouen, France
Vitiligo & Pigmentation Institute of Southern California
🇺🇸Los Angeles, California, United States
Center For Dermatology Cosmetic and Laser Surgery
🇺🇸Fremont, California, United States
Marvel Clinical Research Llc
🇺🇸Huntington Beach, California, United States
Acrc Studies
🇺🇸San Diego, California, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
Wake Research Associates Llc
🇺🇸Raleigh, North Carolina, United States
Kgl Skin Study Center
🇺🇸Broomall, Pennsylvania, United States
Progressive Clinical Research
🇺🇸San Antonio, Texas, United States
Dermatology Research Institute
🇨🇦Calgary, Alberta, Canada
Medical Center Eurohealth
🇧🇬Sofia, Bulgaria
Siena Medical Research Corporation
🇨🇦Westmount, Quebec, Canada
Hopital Archet 2 Derm Dept
🇫🇷Nice, France
Clinica Universidad de Navarra (Cun)
🇪🇸Pamplona, Spain
Colorado Medical Research Center Inc
🇺🇸Denver, Colorado, United States
Avita Clinical Research
🇺🇸Tampa, Florida, United States
Olympian Clinical Research
🇺🇸Tampa, Florida, United States
Wake Forest University
🇺🇸Winston-Salem, North Carolina, United States
Forcare Clinical Research Fcr Forward Clinical Trials, Inc
🇺🇸Tampa, Florida, United States
Clinical Research Partners Llc
🇺🇸Richmond, Virginia, United States
Forest Hills Dermatology Group
🇺🇸Kew Gardens, New York, United States
Dermatology Associates of Plymouth Meeting
🇺🇸Plymouth Meeting, Pennsylvania, United States
Innovative Dermatology
🇺🇸Plano, Texas, United States
Skin Centre For Dermatology
🇨🇦Peterborough, Ontario, Canada